MedTrace Logo

A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects

NCT01567683 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2012-05-28

No results posted yet for this study

Summary

This study is designed to assess the tolerability of test product and vehicle in terms of skin reactions during repeated topical applications on healthy skin under controlled conditions on the basis of the international guidelines for testing of skin irritations (FDA Guidance for Industry (1999)).

Conditions

  • Healthy

Interventions

DRUG

Imiquimod (topical use)

Sponsors & Collaborators

  • Moberg Pharma AB

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01567683 on ClinicalTrials.gov